PROPALIN SYRUP

국가: 말레이시아

언어: 영어

출처: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

지금 구매하세요

제품 특성 요약 제품 특성 요약 (SPC)
19-10-2022

유효 성분:

Phenylpropanolamine hydrochloride

제공처:

Gladron Chemicals Sdn Bhd

INN (International Name):

Phenylpropanolamine hydrochloride

패키지 단위:

30.00 mcg/mL; 100.00 mcg/mL

Manufactured by:

Vetoquinol

제품 특성 요약

                                PROPALIN SYRUP
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT:
Propalin Syrup
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION:
Each ml of product contains:
Phenylpropanolamine hydrochloride ..................50 mg
Corresponding to Phenylpropanolamine........40.28 mg
3.
PRODUCT DESCRIPTION:
colourless solution
4.
PHARMACODYNAMIC PROPERTIES:
The clinical effect of phenylpropanolamine in urinary incontinence is
based on
its stimulation effect on
α
-adrenergic receptors. This causes an increase in, and
a stabilisation of, the closure pressure in the urethra, which is
innervated
mainly by adrenergic nerves.
Phenylpropanolamine is a racemic mixture of D and L enantiomers.
4.1
PHARMACOKINETIC PROPERTIES:
In the dog, the mean half life of phenylpropanolamine is approximately
3 hours with maximal plasma concentrations being found after
approximately 1 hour.
No accumulation of phenylpropanolamine has been observed after a dose
of
1 mg/kg 3 times daily over 15 days. When the product is administered
to a
fasted dog, bioavailability is increased significantly.
5.
INDICATIONS:
Treatment
of
urinary
incontinence
associated
with
urethral
sphincter
incompetence
in
the
bitch.
Efficacy
has
only
been
demonstrated
in
ovariohysterectomised bitches.
5.1
RECOMMENDED DOSAGE:
In bitches: 3mg/kg daily in divided dose given with food i.e. 1.5mg/kg
twice
daily or 1.0mg/kg three times daily e.g. for 25kg dog give 0.75ml
twice daily
or 0.5ml three times daily for a total daily dose of 1.5ml (75mg).
5.2
CONTRA-INDICATIONS:
The use of Propalin is not appropriate for the treatment of
behavioural
causes of inappropriate urination. Do not administer to patients
treated with
non-selective monoamine oxidase inhibitors.
Do not use in case of known hypersensitivity to active substance or to
any of
the excipients.
1. Remove the childproof safety cap by pushing
down firmly and turning anti-clockwise.
2. Take the dosage syringe, with plunger pushed inwards,
and insert the end into the opening of the stopper.
Push down firmly.
3. Hold at an angle, do not fully in
                                
                                전체 문서 읽기
                                
                            

이 제품과 관련된 검색 알림

문서 기록보기